Natera Inc

Analyze Natera’s 10 b5‑1 insider sales: how a 235,000‑share trade by co‑founder Sheena Jonathan and trust holdings affect pricing, liquidity, and investor confidence in the genomics market.

Explore how Natera’s insider‑sale of RSUs signals strong cash flow and the company’s strategy to invest in next‑gen liquid‑biopsy tests, driving growth in the $26 bn genomic diagnostics market.

Read Natera’s latest SEC filing: a senior officer sold shares on May 1, 2026, highlighting the company’s equity‑compensation strategy and its impact on shareholder confidence and corporate governance.

Insightful analysis of Natera’s insider trades shows routine Rule 144/10b‑5‑1 filings, minimal financial impact, and strong governance signals for investors.

Discover how Natera’s Signatera ctDNA test is reshaping bladder‑cancer care with MRD‑guided therapy, market insights, and ASCO presentation highlights.

Explore Natera Inc.’s 2025 earnings and breakthrough Signatera MRD platform—showing 18% revenue growth, 42% gross margin, and clinical data that could shape personalized cancer treatment and reimbursement approvals.

Explore Natera’s high‑accuracy, non‑invasive preconception and prenatal genetic testing—boosting diagnostic precision, reducing invasive procedures, and shaping future reproductive healthcare.

FDA review of Natera’s high‑sensitivity urine test for bladder‑cancer recurrence promises earlier detection, less invasive monitoring, and potential cost savings for patients and payers.

Discover how Natera’s new AI‑driven MRD platform could change oncology care—boosting early relapse detection and tailoring treatment at JHC 2024.

Discover how Natera’s partnership with EXEL aims to expand its liquid‑biopsy portfolio into colorectal cancer diagnostics, tackle reimbursement hurdles, and outpace competitors.